One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study.
The results support the use of mepolizumab as an effective option in the current standard of care for patients affected by severe, uncontrolled CRSwNP especially in decreasing nasal polyps’ size and improving quality of life, although a minor impact was observed on recovery of smell.
Authors
- Caterina Montuori
- Rodolfo Francesco Mastrapasqua (ORCID: https://orcid.org/0000-0002-3558-8081)
- Marco Corbò (ORCID: https://orcid.org/0009-0005-7394-8630)
- Giuseppe Roberto D’Agostino (ORCID: https://orcid.org/0000-0002-2884-0410)
- Angela Rizzi (ORCID: https://orcid.org/0000-0002-6795-746X)
- L. D’Auria (ORCID: https://orcid.org/0009-0007-7101-1080)
- Eugenio De Corso (ORCID: https://orcid.org/0000-0001-5761-7018)
- Jacopo Galli (ORCID: https://orcid.org/0000-0003-1599-4573)
- A Rizzuti (ORCID: https://orcid.org/0009-0005-9826-0517)
- C. Spanu
- Augusta Ortolan (ORCID: https://orcid.org/0000-0002-3131-0939)
- Maria Clara Pacilli
- Gabriele De Maio (ORCID: https://orcid.org/0009-0000-1985-8224)
- Serena Pisciottano (ORCID: https://orcid.org/0009-0005-2487-1219)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Ospedale di Rivoli (IT)
- University of the Sacred Heart (JP)
Publication Details
- Journal
- PubMed
- Published
- 2025-12-01
- DOI
- https://doi.org/10.4193/rhin25.121
- Citations
- 1
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.47